Clinical outcomes and prognostic factors of definitive radiotherapy for esophageal cancer

DOI IR Web Site PubMed 18 References Open Access
  • Tonoiso Chisato
    Department of Radiology, Institute of Biomedical Sciences, Tokushima University,Tokushima, Japan
  • Ikushima Hitoshi
    Department of Therapeutic Radiology, Institute of Biomedical Sciences, Tokushima University,Tokushima, Japan
  • Kubo Akiko
    Department of Radiology, Institute of Biomedical Sciences, Tokushima University,Tokushima, Japan
  • Kawanaka Takashi
    Department of Radiology, Institute of Biomedical Sciences, Tokushima University,Tokushima, Japan
  • Funatani Shunsuke
    Department of Radiology, Institute of Biomedical Sciences, Tokushima University,Tokushima, Japan
  • Kudo Takaharu
    Department of Oral and Maxillofacial Surgery, Institute of Biomedical Sciences, Tokushima University,Tokushima, Japan
  • Yoshida Takahiro
    Department of Thoracic,Endocrine Surgery and Oncology, Institute of Biomedical Sciences, Tokushima University,Tokushima, Japan
  • Miyamoto Hiroshi
    Department of Gastroenterology and Oncology, Institute of Biomedical Sciences, Tokushima University,Tokushima, Japan
  • Harada Masafumi
    Department of Radiology, Institute of Biomedical Sciences, Tokushima University,Tokushima, Japan
  • Takayama Tetsuji
    Department of Gastroenterology and Oncology, Institute of Biomedical Sciences, Tokushima University,Tokushima, Japan
  • Tangoku Akira
    Department of Thoracic,Endocrine Surgery and Oncology, Institute of Biomedical Sciences, Tokushima University,Tokushima, Japan

Search this article

Abstract

<p>Purpose To assess the treatment results of definitive radiotherapy for esophageal cancer at Tokushima University Hospital and clarify the prognostic factors. Methods Seventy consecutive patients with esophageal cancer who underwent definitive radiotherapy between May 2004 and March 2012 were included in the present study. Local control rate, overall survival rate, and radiation morbidity were examined and univariate and multivariate analyses were performed to investigate prognostic factors. Results The 5-yearoverall survival rates of stages I, II, III, and IVA were 81%, 71%, 0%, and 9%, respectively. Performance status, clinical stage, and neoadjuvant chemotherapy were significant prognostic factors. A past history of interstitial pneumonia was associated with severe radiation-induced lung injury. Conclusions Patients who underwent definitive chemoradiotherapy for esophageal cancer in stage I/II showed good prognosis. However, treatment results of the patients in stage III/IV were not satisfactory, and those who could not undergo surgery after neoadjuvant chemotherapy had the worst prognosis.J.Med.Invest.66:99-105, February, 2019</p>

Journal

References(18)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top